Pha-665752

Pha-665752

SCHEMBL140412

Cc1[nH]c(/C=C2\C(=O)Nc3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc32)c(C)c1C(=O)N1CCC[C@H]1CN1CCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 11/20 1.00
FGFR1 P11362 9/20 1.00
PDGFRB P09619 9/20 1.00
MET P08581 7/20 1.00
SRC P12931 6/20 1.00
LCK P06239 4/20 1.00
YES1 P07947 4/20 1.00
CDK2 P24941 2/20 1.00
PTK2B Q14289 2/20 1.00
MEN1 O00255 2/20 1.00
KMT2A Q03164 2/20 1.00
TDP1 Q9NUW8 2/20 1.00
KIT P10721 2/20 1.00
EGFR P00533 2/20 1.00
ALK Q9UM73 2/20 1.00
PLK4 O00444 1/20 1.00
RIOK3 O14730 1/20 1.00
CASK O14936 1/20 1.00
GAK O14976 1/20 1.00
DCLK1 O15075 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pha-665752 SCHEMBL29376386 1.00 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL93656 1.00 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL93657 1.00 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL93655 1.00 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL93654 1.00 KDR (1.00) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL15639801 0.99 KDR (0.99) KDRFGFR1PDGFRBMETSRC
Pha-665752 SCHEMBL15639803 0.99 KDR (0.99) KDRFGFR1PDGFRBMETSRC
SCHEMBL23691031 0.97 KDR (0.94) KDRFGFR1PDGFRBMETSRC
SCHEMBL143795 0.96 KDR (0.93) KDRFGFR1PDGFRBMETSRC
SCHEMBL147331 0.95 KDR (0.91) KDRFGFR1PDGFRBMETSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US claimed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US claimed
US-8846953-B2 Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles SCINOPHARM TAIWAN, LTD. (TW) 2014-09-30 US disclosed
US-8846953-B2 Processes for the preparation of 3-(pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles SCINOPHARM TAIWAN, LTD. (TW) 2014-09-30 US disclosed
US-20140221455-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR Verva Pharmaceuticals, Inc. (AU) 2014-08-07 US disclosed
US-20130190512-A1 PROCESSES FOR THE PREPARATION OF 3-(PYRROL-2-YL)METHYLENE)-2-PYRROLONES USING 2-SILYLOXY-PYRROLES SCINOPHARM TAIWAN, LTD. (TW) 2013-07-25 US disclosed
US-20130190512-A1 PROCESSES FOR THE PREPARATION OF 3-(PYRROL-2-YL)METHYLENE)-2-PYRROLONES USING 2-SILYLOXY-PYRROLES SCINOPHARM TAIWAN, LTD. (TW) 2013-07-25 US disclosed
WO-2012058780-A1 PROCESSES FOR THE PREPARATION OF 3-(PYRROL-2-YL)METHYLENE)-2-PYRROLONES USING 2-SILYLOXY-PYRROLES SCINOPHARM (KUNSHAN) BIOCHEMICAL TECHNOLOGY CO., LTD. (CN) 2012-05-10 WO disclosed
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR VERVA PHARMACEUTICALS PTY LTD (AU) 2012-03-08 US disclosed
US-20050282733-A1 Differentiation modulating agents and uses therefor VERVA PHARMACEUTICALS PTY LTD (AU) 2005-12-22 US disclosed
US-6599902-B2 For treating or preventing a protein kinase related disorder SUGEN, INC. 2003-07-29 US disclosed
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS SUGEN, INC. 2003-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190512-A1 PROCESSES FOR THE PREPARATION OF 3-(PYRROL-2-YL)METHYLENE)-2-PYRROLONES USING 2-SILYLOXY-PYRROLES SKP2, SDHA, MDH2 KDR 15/4885FGFR1 157/4885PDGFRB 285/4885
US-20120059047-A1 DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR FGF1, FABP4, FGF2 KDR 1077/4885FGFR1 5/4885PDGFRB 467/4885
US-20050282733-A1 Differentiation modulating agents and uses therefor FGF1, FABP4, FGF2 KDR 1077/4885FGFR1 5/4885PDGFRB 467/4885
US-20030125370-A1 5-ARALKYSUFONYL-3-(PYRROL-2-YLMETHYLIDENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS DMPK, ADK, MAP3K20 KDR 398/4885FGFR1 637/4885PDGFRB 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.